Citron s allegations have heaped pressure on Valeant , which is already under scrutiny for extreme price hikes on drugs that it has acquired over the years , including investigations launched by federal prosecutors in New York and Massachusetts . That s Wall Street saying , Hey , we don t trust your answer , Left said , referring to Valeant s precipitous fall in price . Endo said on Wednesday that specialty pharmacies accounted for only 3 percent of the company s projected 2015 revenues . Citron has no evidence that Valeant is actually making fake sales .
